Evidence map›Paper›PMID 36304621›Full record

ArticleProceedings (Baylor University. Medical Center)2022

Azacitidine-induced myopericarditis in acute myeloid leukemia.

Mahmoud Ismayl, Asmini Kc, Abhishek Thandra, Nattapong Sricharoen, Amy Arouni

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mahmoud IsmaylDepartment of Internal Medicine, Creighton University School of Medicine, Omaha, Nebraska.ORCID https://orcid.org/0000-0001-9033-7835
Asmini KcDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Abhishek ThandraDivision of Cardiovascular Medicine, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.
Nattapong SricharoenDivision of Cardiovascular Medicine, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.
Amy ArouniDivision of Cardiovascular Medicine, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska.
Creighton University · USUniversity of Nebraska Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypomethylating agents are commonly used in the treatment of myelodysplastic syndromes and are known to cause bone marrow suppression; however, cardiac complications are rare. We describe a patient who was diagnosed with acute myeloid leukemia and developed myopericarditis after receiving chemotherapy with azacitidine. Our case highlights the importance of a thorough history, including medication review, in patients with suspected myopericarditis. It also raises awareness about the potential cardiac side effects of azacitidine.

Indexed as

Acute myeloid leukemiaazacitidinehypomethylating agentsmyopericarditis

Identifiers

PMID36304621
PMCPMC9586640
OpenAlexW4307583461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.